Introduction

Please complete this 2012 survey for organisations which are external stakeholders of the EUnetHTA Joint Action. We ask for one response from your umbrella organisation.

The survey has been designed to be easily completed and should take you no longer than 30-45 minutes (depending on how much you write for the free-text questions).

Your response may be attributed to you unless you indicate otherwise (when it would be kept confidential within the EUnetHTA Joint Action Stakeholder Forum, Executive Committee, Secretariat and the WP3 evaluation team). In exceptional cases we might contact you to ask you for further clarification about responses.

There is no word count limit for your answers and the reply boxes expand.

The EUnetHTA JA Executive Committee requests your early response to this survey and by JUNE 19 at the latest please.

Please click NEXT when you have answered all questions on a page. Click PREVIOUS if you want to go back to the page before. Click FINISH at the end to submit your answers.

Many thanks for your help, Eleanor Guegan (NETSCC, WP3 lead partner), e.guegan@soton.ac.uk

2. EUnetHTA Joint Action (JA) Stakeholders

This section asks for your evaluation about the involvement of external stakeholders in the EUnetHTA JA.

1. Please indicate your agreement with the following statements;

	Strongly Disagree	Disagree	Agree	Strongly Agree	Don't Know
Being an external stakeholder of the EUnetHTA JA has been a good use of my organisation's time	С	0	0	C	O
My organisation has got what it hoped by being an external stakeholder of the EUnetHTA JA	0	0	O	0	0
The EUnetHTA JA Stakeholder Forum has fulfilled its purpose	0	0	0	O	0
The appropriate organisations were included in the Stakeholder Forum	0	0	0	0	0
The formation of a Stakeholder Forum was an effective way of organising Stakeholder input into the EUnetHTA JA	0	0	0	0	0
The Stakeholder Advisory Groups (SAGs) have been a good way of being involved in the EUnetHTA JA	0	0	O	O	0
Our organisation is aware who is our representative on the Stakeholder Forum	0	0	0	0	0
Our organisation has been kept updated by our representative on the Stakeholder Forum/the Secretariat	0	0	O	O	0

Please add any comments;

EUnetHTA JA

This section asks for your evaluation of the EUnetHTA JA.

1. Please indicate your agreement with the following statements;

	Strongly Disagree	Disagree	Agree	Strongly Agree	Don't Know
The EUnetHTA JA has achieved what my organisation hoped	0	C	0	0	0
Stakeholders' views have been adequately considered in the EUnetHTA JA	0	0	0	0	0
Adequate feedback from the EUnetHTA JA has been provided to Stakeholders	0	0	0	0	O
My organisation's expertise has been appropriately used in the EUnetHTA JA	0	0	0	0	0
It would be useful to have a EUnetHTA conference on a regular basis	O	0	0	0	O
Please add any comments;					

۸.

۸.

2. Do you have any concerns about the involvement of external stakeholders in the EUnetHTA JA?

	No	Yes	Don't Know
The principles of stakeholder involvement in the JA (Stakeholder involvement policy and SOP)	O	0	0
The actual involvement of stakeholders in the JA	O	O	0
The level of commitment of stakeholders in the JA	0	0	0

Please explain your answers, if you wish;

3. How has your organisation contributed to the EUnetHTA JA?

4. Lead partners and Co-lead partners decided not to hold a conference at the end of the EUnetHTA JA. Instead there was one in 2011 in Gdansk. Was this the right decision?

O No

O Yes

C Don't Know

۸.

۸.

۸.

۸.

Please explain your answer;

5. What have been the main CHALLENGES of being involved in the EUnetHTA JA?

6. What have been the main BENEFITS of being involved in the EUnetHTA JA?

7. How useful do you think the following will be for the work of professionals producing HTA?

	Not Useful	Of some use	Very useful	Don't Know	
Networking with contacts made from participating in the EUnetHTA JA	0	0	0	C	
The HTA Core Model (the online Tool & Service for producing, publishing, storing and retrieving HTA information) (WP4)	0	0	0	0	
The HTA Core Model on screening (WP4)	0	O	0	O	
A methodological guidance that will be appropriate for the assessment of relative effectiveness of pharmaceuticals (WP5)	0	0	0	O	
Quarterly communication protocol for information flow on ongoing/planned national assessments of same technologies (WP7)	0	0	0	0	
Operational web-based toolkit including database containing information on evidence generation on new technologies (EVIDENT) (WP7)	C	0	0	O	
Accessing the EUnetHTA tools by a single sign-on through the MO site (WP6)	0	0	0	0	
Please add any comments;					

8. Would you like to improve your understanding by having training about developments from the project?

No	Yes	Don't Know
0	O	C
0	0	O
0	0	O
0	O	O
0	O	С
	000000	

Please add any comments;

9. Do you think that the EUnetHTA JA will be successful in achieving its 3 official objectives by the end of the project (December 2012)?

	No	Yes	Don't Know
Development of a general strategy & business model for sustainable European collaboration on HTA.	C	O	0
Development of HTA tools & methods.	O	0	0
Application and field testing of developed tools & methods.	0	C	0

۸

Please describe any concerns about EUnetHTA JA meeting its objectives;

10. Would a sustainable European collaboration add value?

	No	Yes	Don't Know
National level	0	О	O
Regional level	0	0	O
European level	O	0	O

Please explain what value would be added, or why no value would be added;

11. What would make you know that a sustainable European Collaboration on HTA has been achieved?

۸.

۸.

12. Do you have any comments about how EUnetHTA JA has been promoted externally? (500 word limit)

e.g.the promotional leaflet, public website, groups on social networking sites, videos (on Youtube & website) and presence at conferences

13. Please complete the evaluation table for ALL the EUnetHTA JA workpackages;

	Do you have any concerns about this WP?	Will it achieve its objectives by the end of the EUnetHTA JA?	Have you received appropriate communication from this WP?	Has this WP been worth having in the EUnetHTA JA?
WP1: Coordination	_	_	_	_
WP2: Dissemination		•	-	_
WP3: Evaluation		•	•	•
WP4: Core HTA	_	•	•	•
WP5: Relative Effectiveness Assessment of Pharmaceuticals		•	V	
WP6: Information Management System			_	
WP7: New Technologies	_	•	•	•
WP8: Strategy & Business Model Development		T	•	•
Please explain your answe	rs, if you wish;			
				×

5. EUnetHTA Joint Action 2

This section asks for your opinions about the EUnetHTA JA2 and how experiences from the EUnetHTA JA can be used to inform it.

1. Do you think the EUnetHTA JA2 (2012-2015) will serve as a useful follow-up to EUnetHTA JA?

O No

O Don't Know

۵.

۸.

۸.

-

۸

O Yes

Please explain your answer;

2. What are the main learning points from the EUnetHTA JA that should inform the EUnetHTA JA2?

3. What can be learnt from EUnetHTA JA about how to best involve external stakeholders and/or experts in EUnetHTA JA2?

4. How can communication (internal or external) be improved in EUnetHTA JA2?

5. Do you have any concerns about the planned EUnetHTA JA2?

O No

C Don't Know

.

.

C Yes

Please explain any concerns and what could be done about them;

6. What would make ongoing European collaboration on HTA effective?

WP4: Core HTA

This section asks for your evaluation of WP4: Core HTA. Please answer the questions if your organisation feels it can take a view.

1. Has your organisa	tion participated in a s	Stakeholder Advise	ory Group (SAG) for WP4?
O No		C Don't Know	
O Yes			
2. How has WP4 prog	gressed so far?		
C Poorly	OK (but could be better)	C Well	C Don't Know
Please explain any concerns;			

 $\mathbf{\nabla}$

۵.

WP4's workplan lists 3 deliverables - we are interested in your views about them.

3. 'An online Tool & Service for producing, publishing, storing and retrieving HTA information' should be delivered in months 36 - December 2012. Do you think this will happen?

	No	Yes	Don't Know
On time	0	0	C
To a good quality	0	O	O

Please explain any concerns;

4. 'Screening application of the HTA core model' should have been delivered in month 15 - March 2011. Do you think this happened?

	No	Yes	Don't Know
On time	0	0	С
To a good quality	0	O	O

•

۸.

Please explain any concerns;

5. 'A set of two core HTAs' should be delivered in month 36 -December 2012. Do you think this will happen?

	-		
	No	Yes	Don't Know
On time	0	0	O
To a good quality	O	0	0

WP5: Relative Effectiveness Assessment of Pharmaceuticals

This section asks for your evaluation of WP5: Relative Effectiveness Assessment of Pharmaceuticals. Please answer the questions if your organisation feels it can take a view.

1. Has your orga	nisation pa	rticipated in a S	takeholder Adviso	ory Group (SAG) for WP5?				
O No			C Don't Know	Don't Know				
C Yes								
2. How has WP5 progressed so far?								
C Poorly	0 OF	(but could be better)	O Well	O Don't Know				
Please explain any conce	rns;							
				×				
WP5's workplan lists 2 deliv	erables - we are ir	terested in your views ab	out them.					
3. 'A relative effe	ectiveness a	assessment of a	(group) of					
pharmaceutical(
month 30-31- Ju	ne - July 20	12.						
Do you think this								
On time	No	Yes	Don't Know					
To a good quality	O	0	Ō					
Please explain any conce	rns;							
				×				

$\ensuremath{\textbf{4}}$. 'A methodological guidance that will be appropiate for the

assessment of relative effectiveness of pharmaceuticals'

should be delivered in month 36 - December 2012.

No Yes Don't Know On time O O To a good quality O O

۸.

Please explain any concerns;

5. Is there anything else you want to say about WP5?

EUnetHTA JA Stakeholders' Final Survey 2012					
NP7: New Tech	nnologies				
	your evaluation of WP7: New Technologies. lestions if your organisation feels it can take a view.				
1. Has your orga	nisation participated in a Stakeholder Advisory Group	(SAG) for WP7?			
C No	O Don't Know				
C Yes					
2. How has WP7	progressed over the past year?				
C Poorly	C OK (but could be better) C Well C Don't P	Know			
Please explain any concer	rns;				
	erables - we are interested in your views about them.	Y			
technologies, sh 2012.	nation on evidence generation on new ould be delivered in month 33-September				
additional evider	database will be successful in facilitating nce generation?				
С No	O Don't Know				
C Yes					
Please explain any concer	rns:				
		*			

4. 'Criteria to select/prioritize health technologies in need of additional evidence generation' should be delivered in month						
30 - June 2012.						
Do you think these criteria will be useful?						
C No	O Don't Know					
C Yes						
Please explain any concerns;						

5. Is there anything else you want to say about WP7?

Survey End

1. Is there anything else you would like to say about the EUnetHTA JA?

2. Please estimate the time it has taken you (in minutes) to complete this survey

Many thanks for completing this survey!

Please click on the 'Finished' button below to submit your answers.